Yvonne L. Greenstreet Salary and Compensation - Alnylam Pharmaceuticals, Inc. CEO Salary 2025

In fiscal year 2025, Yvonne L. Greenstreet, M.D. Chief Executive Officer (principal executive officer) of Alnylam Pharmaceuticals, Inc. (ALNY), received total compensation of $14.9 million.

Yvonne L. Greenstreet's compensation breakdown includes: base salary of $1.4 million, stock awards valued at $5.5 million, option awards of $4.4 million, non-equity incentive compensation of $3.6 million, and other compensation of $25K.

Compared to fiscal year 2024, Yvonne L. Greenstreet's total compensation increased 29% from $11.5 million to $14.9 million.

Alnylam Pharmaceuticals, Inc. (ALNY) Executive Pay 2025

Alnylam Pharmaceuticals, Inc.'s top 5 named executive officers received combined total compensation of $41.2 million in fiscal year 2025.

The named executive officers disclosed in Alnylam Pharmaceuticals, Inc.'s 2025 proxy statement are:Yvonne L. Greenstreet (M.D. Chief Executive Officer (principal executive officer)) with total compensation of $14.9 million, Jeffrey V. Poulton (Executive Vice President Chief Financial Officer (principal financial officer)) with total compensation of $6.9 million, Bryan A. Supran (Executive Vice President Chief Legal Officer and Secretary) with total compensation of $6.8 million, Pushkal Garg (M.D. Executive Vice President, Chief Research and Development Officer) with total compensation of $6.5 million, and Tolga Tanguler (Executive Vice President Chief Commercial Officer) with total compensation of $6.1 million.